TIGIT and neoplasm: In particular, we found that the NECTIN2-TIGIT immune coinhibitory interactions, mediated by the NECTIN2 ligand expressed on tumor cells and the TIGIT receptor expressed on immune cells, were prevalent during the histologic progression.